Tolmar Announces Acquisition of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio

-  Launched in 2020, JATENZO was the first oral softgel testosterone medicine approved in the US by the FDA in more than 60 years
-  JATENZO is an oral softgel testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired)
-  Compelling fit with Tolmar's strategy to acquire and develop therapies targeting diseases and conditions in Urology, Oncology and Orphan Diseases leveraging the company's focus and commitment in Urology community and Men's Health